1453049

Naloxone Related Compound D CII

United States Pharmacopeia (USP) Reference Standard

• Synonym(s): (4R, 4aS, 7aR, 12bS)-3-allyl-4a,9-dihydroxy-2,3,4,4a-tetrahydro-1H,4,12- methanobenzofuro[3,2-e]-isoquinolin-7(7aH)-one
• Empirical Formula (Hill Notation): C₁₉H₁₉NO₄
• CAS Number: 26451-92-3
• Molecular Weight: 325.36
• UNSPSC Code: 41116107
• NACRES: NA.24

Properties

• API family: naloxone
• packaging: pkg of 25 mg
• manufacturer/tradename: USP
• application(s): pharmaceutical (small molecule)
• format: neat
• storage temp.: 2-8°C

Description

General description

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Application

• Interactive effects of opioid and adrenergic-α2 receptor agonists: Research highlights the complex interactions between µ-opioid and adrenergic-α2 receptor agonists in rats, focusing on the primary Kratom alkaloid Mitragynine and its metabolite 7-Hydroxymitragynine. This study is pivotal for understanding the biochemical pathways involved in opioid receptor antagonist research, offering insights into naloxone-related compound applications in opioid addiction and withdrawal management (Hiranita et al., 2022).


• Diels-Alder reactions of morphinan derivatives: The synthesis and transformations of Diels-Alder adducts of morphinan-6,8-dienes are discussed, illuminating the role of naloxone analogs in synthesizing novel opioid receptor antagonists. These findings contribute to the opioid antagonist research, particularly in exploring structural analogs of naloxone for enhanced therapeutic effects (Marton et al., 2022).


• Impact of brain metastases on methylnaltrexone: A post hoc analysis of three randomized studies investigates the influence of brain metastases on the CNS effects of methylnaltrexone. This research underlines the importance of naloxone derivatives in modifying opioid-induced side effects, which is crucial for the development of safer opioid antagonists in supportive cancer care (Brenner et al., 2021).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  

Other Notes

Sales restrictions may apply.

Safety Information

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 13 - Non Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable